111005-70-0

Upstream product

• 111005-69-7 (-)-9-<2',3'-(cyclohexylidenedioxy)cyclopent-4'-enyl>adenine 
• 111005-65-3 (-)-2,3-(cyclohexylidenedioxy)-4-cyclopentenone 
• 111005-67-5 (3R,4S,5S)-3,4-O-cyclohexylidenecyclopentane-3,4,5-triol 
• 111005-68-6 (-)-2,3-(cyclohexylidenedioxy)-1-<(p-tolylsulfonyl)oxy>cyclopent-4-ene 
• 153737-56-5 (+)-<(1'R,4'S)-4'-trimethylacetoxy-2'-cyclopenten-1'-yl>-9-H-adenine 
• 150018-18-1 9-[(1'R,2'S,3'R,4'S)-2',3',4'-trihydroxycyclopentan-1'-yl]-9-H-N⁶-benzoyladenine 
• 332187-86-7 Methanesulfonic acid (3aS,4R,6R,6aS)-6-(6-amino-purin-9-yl)-2,2-dimethyl-tetrahydro-cyclopenta[1,3]dioxol-4-yl ester 
• 263721-47-7 9-[(1R,2S,3S,4S)-2,3-O-isopropylidene-4-(methanesulfonyloxy)cyclopentan-1-yl]-9H-adenine 
• 332187-84-5 Acetic acid (1R,2S,3S,4R)-4-(6-amino-purin-9-yl)-2,3-dihydroxy-cyclopentyl ester 
• 332187-85-6 (3aR,4R,6R,6aS)-6-(6-Amino-purin-9-yl)-2,2-dimethyl-tetrahydro-cyclopenta[1,3]dioxol-4-ol 
• 332187-83-4 Acetic acid (1R,4R)-4-(6-amino-purin-9-yl)-cyclopent-2-enyl ester 
• 150018-17-0 9-[(1'R,4'S)-4'-hydroxy-2'-cyclopenten-1'-yl]-9-H-N⁶-benzoyladenine 
• 153830-48-9 (-)-β-(4'β-hydroxy-2'α,3'α-O-isopropylidenedioxycyclopent-1'-yl)-9-H-adenine 
• 4005-49-6 N-benzoyladenine 

Downstream Products

• 125409-63-4 9-[(1'R,2'S,3'R)-2',3'-dihydroxycyclopentanyl]adenine 

Relevant academic research and scientific papers

An efficient Mitsunobu coupling to adenine-derived carbocyclic nucleosides

Adenine is a poor substrate for the Mitsunobu process to carbocyclic nucleosides. However, N-6 amino bis-Boc-protected adenine is reported herein to undergo an efficient coupling under these conditions as a result of its increased solubility and the reduc

Expeditious enantioselective synthesis of carbocyclic nucleosides with antileishmanial activity

A short synthesis of the neplanocin A analogue 1, lacking the hydroxymethylene at C-4 of the parent naturally occurring carbocyclic nucleoside, is described. Moreover, the non toxic noraristeromycin 3, an intermediate in the synthetic scheme, was shown to exhibit a promising anti-leishmanial activity.

3-DEAZANEPLANOCIN DERIVATIVES

This invention describes the series of compounds based on the 3-deazaneplanocin A (DZNep) core structure designed to inhibit the function of Polycomb repressive complex 2 (PRC2) proteins.

Facile synthesis of 9-[(1′R,2′S)-2′-hydroxy-3′-oxocyclopentan-1′ -yl]-9-H-adenine possessing inhibitory activity against human recombinant S-adenosyl-L-homocysteine hydrolase

Treatment of 4′-O-methanesulfonyl-2′,3′-O-isopropylidenenoraristeromy cin with KOBut gave the corresponding 3′,4′-dehydro derivative, and subsequent deprotection resulted in the formation of 9-[(1′R,2′S)-2′-hydroxy-3′-oxocyclopentan-1′ -yl]-9-H